Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Amisulpride · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Amisulpride | DRUG | - |
Inclusion Criteria: Pre-Inclusion Criteria on D-3: * In-patients * From 18 to 65 years old * Able to comply with the protocol * Having given their written informed consent (with a legal representative or a person of trust) * Current diagnosis of bipolar I disorder according to DSM IV TR (APA 2000)...
Amisulpride is an investigational small molecule being studied for the treatment of Bipolar Disorder. It is currently in Phase 2 clinical development. The drug is being evaluated in patients with bipolar I disorder, specifically in combination with valproate, as part of a clinical trial.
Amisulpride is being developed by Sanofi, a multinational pharmaceutical company. Sanofi is listed on the stock exchange under the ticker symbol SNY. The company is conducting clinical research to evaluate the safety and efficacy of Amisulpride for the treatment of Bipolar Disorder.
Amisulpride is currently in Phase 2 clinical development for Bipolar Disorder. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The drug is being studied in a clinical trial to assess its potential as a treatment for this condition.
Amisulpride has been studied in a Phase 2 clinical trial with the identifier NCT00126009, titled 'SOLMANIA - Comparison of Valproate-Amisulpride and Valproate-Haloperidol in Bipolar I Patients'. This trial has been completed and enrolled 120 participants across multiple countries, including Czechia, France, Poland, Slovakia, and Spain.
Amisulpride is a distinct drug entity and is not known to be the same as any other drug under a different name. It is being investigated as a potential treatment for Bipolar Disorder, and its development is being conducted by Sanofi.